On June 2, 2025, FDA Commissioner Dr. Martin Makary responded in a letter to Senator Josh Hawley’s inquiry about the safety of the abortion pill mifepristone.
Dr. Makary emphasized the FDA’s ongoing commitment to rigorous scientific review and postmarketing safety monitoring of the drug but noted that pending litigation limits the agency’s ability to provide further details at this time.
This response comes shortly after the National Right to Life Committee sent a detailed letter urging the FDA to reconsider its approval and deregulation of mifepristone based on a new large-scale study revealing significant real-world complications.
FDA chief Marty Makary just committed to me to do a full review of the chemical abortion drug’s safety: “As Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone” 👇 pic.twitter.com/nMxUhE18UA
— Josh Hawley (@HawleyMO) June 3, 2025